Physician profile
Patrick Tomak
NPI 1659387256
$10,147.39
in general payments reported to CMS, 2019-2025
10 companies · $3,866 in 2025
The $3,866 reported for 2025 was more than what 78% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.38 · 2020: $137 · 2021: $367 · 2022: $1,765 · 2023: $154 · 2024: $3,814 · 2025: $3,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,047 · Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,046.90 |
| Food and Beverage | $787.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Expanding Innovations, INC. | $7,143.14 | 2024-2025 | X-Pac |
| Globus Medical, INC. | $1,607.93 | 2021-2025 | Xlif, Affirm, Hedron P |
| Depuy Synthes Sales INC. | $591.98 | 2019-2025 | Teligen, Conduit, Expedium Verse |
| Stryker Corporation | $425.74 | 2020-2022 | |
| Intrinsic Therapeutics | $116.31 | 2022 | |
| Smith+Nephew, INC. | $115.78 | 2024 | Evos |
| Si-Bone, INC. | $74.82 | 2020 | |
| Boston Scientific Corporation | $26.93 | 2023 | |
| Bioventus LLC | $22.90 | 2019 | |
| Medtronic, INC. | $21.86 | 2024 | Vanta Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,693.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Tomak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.